This study is testing a new antibody treatment called **COM701** for people with ovarian cancer who have responded to platinum-based chemotherapy before but whose cancer has come back. The study wants to see if **COM701** can delay the need for another cancer treatment and find out if it is safe to use. Participants will visit the clinic every 3 weeks for treatment through an **IV** (a tube that goes into a vein) and undergo several tests like **CT** or **MRI** scans to check the tumor's status.
- Visits: Clinic visits every 3 weeks.
- Trial Design: 33% chance of receiving placebo, 67% chance of receiving COM701.
- Eligibility: Must have ovarian, fallopian, or primary peritoneal cancer and meet other health criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand